Skip to content

EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE

Menu

About us
Contact us

Myeloma and AL Amyloidosis
- About Myeloma
- About AL amyloidosis
What we do
- Member and patient community programmes
  Myeloma Awareness Month 2025
  
  MPE Masterclass
  
  Scholarship programme
  
  Myeloma CABs
  
  MPE Myeloma and AL amyloidosis Community Taskforce
  
  Advocate Development Programme
  
  European Young Myeloma Patients Group
  
  Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
  
  Research
  Patient Evidence
  
  Horizon Europe
  
  IMI
  
  Access and Policy
  Myeloma Access Atlas
  
  CEE workgroup on Access
  
  Myeloma and AL amyloidosis Clinical Trial Navigator
  
  EU HTA regulation
Educational Resources
European Myeloma Day
News

Myeloma and AL Amyloidosis
- About Myeloma
- About AL amyloidosis
What we do
- Member and patient community programmes
  Myeloma Awareness Month 2025
  
  MPE Masterclass
  
  Scholarship programme
  
  Myeloma CABs
  
  MPE Myeloma and AL amyloidosis Community Taskforce
  
  Advocate Development Programme
  
  European Young Myeloma Patients Group
  
  Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
  
  Research
  Patient Evidence
  
  Horizon Europe
  
  IMI
  
  Access and Policy
  Myeloma Access Atlas
  
  CEE workgroup on Access
  
  Myeloma and AL amyloidosis Clinical Trial Navigator
  
  EU HTA regulation
Educational Resources
European Myeloma Day
News

Day: February 28, 2025

Europe’s Beating Cancer Plan and its progress to date on rare cancers

Access, latest, NewsFebruary 28, 2025

Myeloma Patients Europe AISBL

Avenue Louise 143/4, 1050
Brussels Belgium
© Myeloma Patients Europe 2025

Contact
About us
Privacy policy
Terms and conditions
Cookies Policy

About MPE
Contact us
Myeloma and AL Amyloidosis
- About Myeloma
- About AL amyloidosis
What we do
Educational Resources
News
European Myeloma Day

PopUp

I am a*
- Patient
- Patient advocate
- Caregiver
- Doctor
Name
This field is for validation purposes and should be left unchanged.